Advertisement

Topics

Companies Related to "Global Development secures future drug candidate development CollegeHill" [Most Relevant Company Matches] - Page: 2 RSS

16:47 EDT 25th March 2019 | BioPortfolio

Here are the most relevant search results for "Global Development secures future drug candidate development CollegeHill" found in our extensive corporate database of over 50,000 company records.

Showing "Global Development secures future drug candidate development CollegeHill" Companies 26–50 of 13,000+

Relevant

Knopp Neurosciences Inc.

Knopp Neurosciences, based in Pittsburgh, PA, USA, is a drug discovery and development company focused on delivering breakthrough treatments for neurological disorders through innovation, experience, and partnership. The company’s lead product candidate is KNS-760704, an orally bioavailable small molecule in development for the treatment of ALS. Knopp...


PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees ...

Covance Market Access Services Inc.

Covance — one of the world's largest and most comprehensive drug development services companies — has the people, global resources and problem-solving culture to respond to pharmaceutical and biotechnology clients' toughest drug development challenges. We provide a portfolio of preclinical and clinical development and commercial service offerings — delivered through industry-leading nonclin...


CMO Consulting, Inc.

CMO Consulting is led by Edward Garmey, M.D. a former academic hematologist-oncologist at Memorial Sloan-Kettering Cancer Center with a successful industry track-record comprising over a decade of senior leadership experience including seven prior CMO roles. CMO Consulting provides its clients, ranging from blue-chip venture capital firms to start-ups and ...

StemCells, Inc.

StemCells, Inc. is focused on the development and commercialization of cell-based technologies. In its cellular medicine programs, StemCells is targeting diseases of the central nervous system and liver. StemCells’ lead product candidate, HuCNS-SC® cells (purified human neural stem cells), is in clinical development for the treatment of two fatal n...

ChemPharmaServe

The art of discovering new drugs has come a long way, but it is still not possible to design new medicines in the lab and then take them directly to production factories. For the foreseeable future, all new drug candidates need to pass through preclinical and clinical development stages before emerging as real medicines. Conducting preclinical and clinical development studies requires access to a...

Neurogenetic Pharmaceuticals, Inc.

Neurogenetic Pharmaceuticals, Inc. (NGP) is a biopharmaceutical discovery and development company founded in 2009 which is focused on developing innovative drug therapies for use in the treatment of neurodegenerative disorders such as Alzheimer’s disease. Based in San Diego, Calif., the company’s next objective is to obtain an Investigational New...

Lumos Pharma, Inc.

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and is funded by leading healthcare investors, including Deerfield, NEA, Clarus,...

Lantern Pharma Inc.

Lantern Pharma is a biotech company aiming to re-invent the cancer drug development process by tailoring promising drug programs to the right cancer patients through biomarker discovery. Lantern leverages advanced genomics and machine learning based artificial intelligence (AI) to identify and significantly reduce the cost and overall risk profile of new t...

GeneSegues

GeneSegues is a biopharmaceutical company built upon advanced, targeted drug delivery technology. We conduct research and early-stage development of proprietary oncology biopharmaceuticals using our ligand-directed, nanoencapsulation technology. Our two initial product candidates are antisense therapeutics for treatment of advanced head neck and prostate cancers. We are currently conducting animal...

PHARMATARGET

PharmaTarget is a biotechnology company, which was founded in 2002 in Maastricht, The Netherlands, provides products and services to pharmaceutical and biotech companies, that are active in the field of drug discovery and development.In general, biotech and pharmaceutical companies face extensive experimental periods in determining the effectiveness of newly developed drug compounds. Scarce resour...

Novosis AG

Novosis AG is a pharmaceutical company with its main focus on research and development of dermal drug delivery systems.Novosis AG offers contract development work based on either clients' own drug molecules or product concepts Novosis AG's conceptual and practical expertise is established in:development and manufacturing of transdermal drug delivery systems (TTS, TDS, patches), development and man...

REVOTAR Biopharmaceuticals AG

Revotar Biopharmaceuticals AG is a privately owned, independent German biopharmaceutical company located in Hennigsdorf close to Berlin. Revotar develops innovative small molecule anti-inflammatory drugs for indications such as asthma, psoriasis, sepsis, COPD and other inflammatory indications.Revotar was founded in 2000. The Company was endowed from the start with the asset bimosiamose, an innova...

Aprea AB

Aprea AB is a Swedish biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea's main shareholder is KDev Investments AB, an investment vehicle owned by Karolinsk...

genOway Germany GmbH

The development of a new drug costs roughly 800 M.USD. This huge investment has to cover both the development of the drug itself and the cost of unfruitful work. Dead-ends can represent up to 80% of the total cost of a successful drug. Major challenges in the drug development process are (1) to reduce high failure rates due to faulty candidate selection and false positives and (2) to identify all ...

Triangle Pharmaceuticals Incorporated

Triangle Pharmaceuticals develop new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV, including AIDS, and the hepatitis B virus ("HBV"). Triangle Pharmaceuticals have an existing portfolio of six licensed drug candidates and one drug candidate for which they have an option to acquire a license. Five of these drug candidates are currently under active d...

Curis

This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Curis' future financial position, business strategy and plans and objectives of management for future operations. We may use such words as "believes," "expects," "anticipates," "plans," "estimates," and similar expressions to identify these for...

Bio Dynamics

BioDynamics was established in 1992 with the objective of providing high quality drug discovery and development services to the global pharmaceutical industry.Bringing together specialists from the three disciplines of metabolism, bioanalysis and isotope chemistry has allowed BioDynamics to offer a truly integrated drug discovery and development programme. The services available provide a seamless...

Knopp Biosciences LLC

Knopp Biosciences LLC, based in Pittsburgh, PA, USA, is a drug discovery and development company focused on delivering breakthrough treatments for unmet medical needs through innovation, experience, and partnership. The company’s lead product candidate is KNS-760704, an orally bioavailable small molecule in development for the treatment of ALS under a...

Selexis SA and Hoba Therapeutics

Selexis SA is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 100 drug products in clinical dev...

Selexis SA and Berkeley Lights, Inc.

Selexis SA is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 100 drug products in clinical dev...

TPP Global Development Ltd

TPP is a UK-based, drug development company operating in the preclinical area of the drug discovery process. TPP in-licenses novel intellectual property (IP) from universities, research institutes and other drug companies and develops this IP into preclinical drug assets that are then sold to large Pharma / Biotech companies, or spun out into separate comp...

The Debiopharm Group

Debiopharm Group(TM) (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III. Debiopharm is also prepared to consider earlier st...

Shimadzu Biotech

Shimadzu Biotech is a strategic global business unit of Shimadzu Corporation, one of the world’s largest instrument manufacturers with annual instrument sales of $1 billion. Shimadzu Biotech is focused on providing integrated solutions for life science and drug development to accelerate the progress of biotechnology in research and development. This vision is a key part of the Shimadzu Corporati...

GlycoGenesys Incorporated

GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life threatening or debilitating diseases. The company's lead drug candidate, GCS-100, formerly known as GBC-590, is a potential treatment for multiple forms of cancer. We plan t...


More From BioPortfolio on "Global Development secures future drug candidate development CollegeHill"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks